We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

PHNX:LSEPhoenix Group Holdings plc Analysis

Data as of 2026-03-14 - not real-time

£691.00

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Standard Life PLC (PHNX) trades at 691 GBp, sitting below its 20‑day (734 GBp) and 50‑day (737 GBp) simple moving averages, indicating short‑term weakness. Technical momentum is bearish with a MACD line well under its signal (-12.7 vs -6.4) and a histogram confirming downward pressure, while the RSI at 36 suggests the stock is approaching oversold territory but not yet in the extreme range. Fundamentally, the company reports a 31% revenue decline, negative profit margins and a forward PE of 1,096, highlighting severe earnings pressure. The balance sheet shows ample cash (≈£10 bn) but a high debt‑to‑equity ratio of 193%, raising leverage concerns. Despite a lofty dividend yield of 7.13%, the payout ratio of 51% is built on negative earnings, making the dividend sustainability doubtful. Volatility is elevated at ~26% over the past 30 days, yet beta remains low, indicating limited market‑wide systematic risk. Analyst consensus holds a “hold” rating with a median price target of 761 GBp, offering roughly a 10% upside from current levels. Recent news confirms the rebranding to Standard Life, but no material operational changes have been disclosed. The market sentiment index leans toward “greed,” suggesting optimism that may not be fully supported by the underlying fundamentals. Overall, the stock faces a mix of technical downside pressure, weak earnings outlook, and an attractive but potentially unsustainable dividend.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 5/10

Key Factors

  • Bearish MACD and price below short‑term SMAs
  • RSI near oversold but no clear reversal signal
  • High dividend yield with questionable sustainability

Medium Term

1–3 years
Neutral
Model confidence: 6/10

Key Factors

  • Analyst median target of 761 GBp implying modest upside
  • Forward EPS turning positive
  • Strong cash position offset by high leverage

Long Term

> 3 years
Cautious
Model confidence: 7/10

Key Factors

  • Persistent negative profitability and high forward PE
  • Elevated debt‑to‑equity ratio and weak margin profile
  • Dividend likely to be cut if earnings do not improve

Key Metrics & Analysis

Financial Health

Revenue Growth-31.30%
Profit Margin-3.44%
P/E Ratio1096.2
ROE-25.37%
ROA-0.01%
Debt/Equity193.41
P/B Ratio609.2
Op. Cash Flow£1.3B
Free Cash Flow£5.0B
Industry P/E16.4

Technical Analysis

TrendNeutral
RSI36.3
Support£676.45
Resistance£774.50
MA 20£734.48
MA 50£737.42
MA 200£686.07
MACDBearish
VolumeIncreasing
Fear & Greed Index72.88

Valuation

Fair Value£6,724.03
Target Price£758.10
Upside/Downside9.71%
GradeOvervalued
TypeValue
Dividend Yield0.07%

Risk Assessment

Beta0.29
Volatility26.00%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.